StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock analysis

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$50.10−0.20 (-0.40%)

Close on Nov 12, 2026Market cap $10.87BP/E 25.8Yield 0.50%

StockData Score

Prices as of Nov 11, 2026How the score works

Value0Growth2Performance4Health4Dividend0

Mixed10 of 30 checks passed

Qiagen passes 10 of the 30 checks behind our score; 13 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
4/6
Financial health
4/6
Dividend
0/6

What stands out

  • Earnings grew over 5 years

    Net income grew 3.4% a year on average over the last five fiscal years.

  • Earnings growth accelerating

    Net income grew 408% over the last twelve months, against a 5-year average of 3.4% a year.

  • Interest well covered

    Operating income covers interest expense 14.0 times.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 39.5% of total debt.

What to watch

  • Return on equity under 15%

    Return on equity was 11.6% over the last twelve months and averaged 10.7% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 9.9%, below the 10% that usually covers the cost of capital.

  • High debt

    Debt is 43.8% of shareholders' equity, above the 40% we consider low.

  • Revenue growing under 10% a year

    Revenue grew -0.8% a year over the last three fiscal years, short of the 10% we look for.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B against the industry

    Needs positive book value.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -0.8% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew 1.8% a year over the last three fiscal years.

  • Earnings growth accelerating

    Net income grew 408% over the last twelve months, against a 5-year average of 3.4% a year.

  • Growing slower than the industry

    Revenue grew 5.7% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 62.2% over the last twelve months, against 48.9% a year earlier.

Past performance4/6

  • Return on equity under 15%

    Return on equity was 11.6% over the last twelve months and averaged 10.7% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was 9.9%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Qiagen's return on equity of 11.6% is above the Drugs median of -58.9%.

  • Earnings grew over 5 years

    Net income grew 3.4% a year on average over the last five fiscal years.

  • Net margin above its 5-year average

    Net margin was 20.3% over the last twelve months, against a 5-year average of 16.9%.

  • Net margin above the industry

    Qiagen's net margin of 20.3% is above the Drugs median of -53.0%.

Financial health4/6

  • High debt

    Debt is 43.8% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 68.7% five years ago to 43.8%.

  • Debt covered by cash flow

    Operating cash flow over the last twelve months equals 39.5% of total debt.

  • Interest well covered

    Operating income covers interest expense 14.0 times.

  • Short-term assets cover short-term debts

    Current assets are 3.90 times current liabilities.

  • Bankruptcy risk (Altman Z)

    Needs market value, working capital and retained earnings.

Dividend0/6

  • No dividend

    Qiagen has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Qiagen. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$254.14M
Value traded per 1% price move
$78.56M

Downside

Medium risk

Typical loss in a bad month
20.1%
Volatility (annualized)
35%
Sharpe ratio, 1 year
0.18
Beta to the S&P 500 (5Y)
0.68

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

62.2%−3.7 pts over 5 years

Operating margin

22.3%+1.6 pts over 5 years

Net margin

20.3%+1.1 pts over 5 years

See a number that looks wrong?